【摘要】 目的 探讨丙戊酸镁缓释片联合齐拉西酮治疗双相障碍躁狂发作的疗效和安全性。方法 将76例双相障碍躁狂发作患者随机分为两组,均口服丙戊酸镁缓释片治疗,研究组联合齐拉西酮治疗,对照组联合利培酮治疗,观察6周。采用Bech-Rafaelsen躁狂量表评定临床疗效,副反应量表评定不良反应。结果 治疗后两组Bech-Rafaelsen躁狂量表评分均较治疗前显著下降(P<0.01),治疗6周末研究组痊愈率52.6%,总有效率84.2%,对照组分别为47.4%、86.8%,两组比较差异无显著性(χ～2=0.21、0.21,P>0.05)。两组不良反应均轻微,但研究组月经改变、泌乳、体质量增加发生率显著低于对照组(P<0.05)。结论 丙戊酸镁缓释片联合齐拉西酮治疗双相障碍躁狂发作疗效显著,几乎不引起体质量增加、泌乳、月经改变,安全性高,依从性好,更适用于女性患者。更多还原

【Abstract】 Objective To explore the efficacy and safety of magnesium valproate sustained-release tablets(MVSRT) plus ziprasidone in the treatment of manic episode of bipolar disorder.Methods Seventy-six patients with bipolar mania patients were randomly divided into two groups,both groups took orally MVSRT,research group was plus ziprasidone,and control group plus risperidone for 6 weeks.Efficacies were assessed with the Bech-Rafaelsen Mania Rating Scale(BRMS) and adverse reactions with the Treatment Emergent Symptom Scale(TESS).Results After treatment the BRMS scores of both groups lowered more significantly compared with pretreatment(P<0.01),at the end of the 6～(th) week cure and total effective rate were respectively 52.6%and 84.2%in research and 47.4%and 86.8%in control group,which showed no significant group differences(x～2 =0.21,0.21,P>0.05).Adverse reactions of both groups were mild,but the incidences of menstrual change,lactation and weight gain were significant lower in research than control group(P<0.05).Conclusion MVSRT plus ziprasidone has an evident effect,almost don’t cause weight gain,lactation and menstrual change,has higher safety and better compliance in the treatment of manic episode of bipolar disorder,and are more suitable for female patients.更多还原